A Retreat to Remember
The absolute highlight of the week was our first annual Lombardi Comprehensive Cancer Center Consortium retreat, which was held on Friday night and Saturday. Supported by a generous donation, the retreat had a singular objective — to create actionable outcomes such as collaborative grants and investigator-initiated clinical trials that leverage our strengths across the consortium.
|
|
Register for the 2023 MedStar Health-Georgetown University Research & Education Symposium |
|
For the first time in three years, the MedStar Health-Georgetown University Research & Education Symposium will be held in person. Join investigators, educators, executive leaders, associates and collaborative partners from across our academic health center on Monday, May 8 at the Bethesda North Marriott Hotel & Conference Center to share research and build relationships that will further advance health in our community. Learn more about the symposium and register by April 28.
|
|
Call for Applications: GUMC Gap Fund Program
The Office of Technology Commercialization has launched its third funding cycle under the GUMC Gap Fund Program to support researchers with innovative ideas. In collaboration with the Office of Advancement, the fund is made possible through a $1 million philanthropic gift from Bill and Ruth Baker. To learn more about eligibility requirements and how to apply, visit the Gap Fund page. The deadline to submit a letter of intent is April 10.
|
|
Shared Resources Spotlight |
|
This weekly series showcases Georgetown University’s Shared Resources, which provide Georgetown Lombardi researchers with access to state-of-the-art equipment and technical expertise to support their work. |
|
Shared Resource Spotlight: Genomics and Epigenomics Shared Resource
The Genomics and Epigenomics Shared Resource (GESR) provides Georgetown Lombardi investigators with access to diverse, state-of-the-art services for genomic and epigenomic studies. Services include DNA/RNA quality assessment, mRNA and miRNA expression profiling, DNA sequencing, single nucleotide polymorphism (SNP) genotyping, copy number variation (CNV) analysis, DNA methylation analysis, and label-free molecular interaction analysis using Biacore Surface Plasmon Resonance (SPR). The GESR uses a variety of platforms for these services, including bioanalyzer, microarray, next-generation sequencing (NGS), real-time PCR, count-based expression analysis (NanoString), and Biacore (SPR). New services include single-cell RNA-seq, digital spatial profiling (DSP) of nucleic acids and proteins, and targeted methyl-seq. To facilitate these services, the GESR organizes education and training on emerging technologies, and it provides bioinformatics support and access to software tools and several user-operated instruments.
New technologies now available: Targeted methyl-seq using the Fluidigm Juno and Illumina MiSeq; digital spatial profiling using the NanoString GeoMX DSP.
|
|
Tuesday, April 4
11:00 a.m. - 12:00 p.m.
|
|
Brain Tumor Working Group Meeting
Thursday, April 6
4:00 - 5:00 p.m.
|
|
IO/Heme Working Group Meeting
Thursday, April 6
5:00 - 6:00 p.m.
Suneel Kudaravalli, PharmD, medical science liaison with medical affairs at Replimune, Inc., presents “IGNYTE Study Update: RP1 + Nivolumab in Anti-PD1 Failed Cutaneous Melanoma.” Join this meeting via Zoom.
|
|
Wednesday, April 5
12:30 - 2:00 p.m.
Presented by Rose Ermete, RN, BSN, OCN, CRN-BC, CCRP, senior quality assurance nurse auditor, SWOG Cancer Research Network, and Deborah Grady, BSN, MS, CCRC, quality management coordinator, National Cancer Institute. Sponsored by the Office of Human Subject Protections. Register for this Zoom seminar and others in the series.
|
|
Funding and Award Opportunities |
|
NEW 2023 Call for V Scholar Cancer Research Grant Applications
The V Scholar Award supports young tenure-track faculty early in their cancer research career by funding projects that are either laboratory-based fundamental research or translational research. This RFA is specifically for adult cancer research that is focused on laboratory research. This year, we have special interest and funding for therapeutic resistance and welcome research projects in this area. Please note that research areas not included in this scope are epidemiology, behavioral science, and health services research. We strongly encourage applications from underrepresented minorities in cancer research. The total amount of the grant is $600,000, paid in three annual installments of $200,000. View full RFA. Those interested in applying should submit a letter of intent (less than one page) to Sharon Levy (sgl5@georgetown.edu) by Friday, April 21, COB. Completed Nomination Form, Letter of Recommendation, and Financial Worksheet due April 27; applications due June 1.
|
|
NEW Phi Beta Psi Grant Proposal Invitation
The goal of the Phi Beta Psi Charity Trust is to advance cancer research nationwide to improve prevention, diagnosis and treatment by providing research grants to qualified investigators addressing original questions and hypotheses to be explored in basic and clinical studies in the field of cancer. Research applications must be focused on brain, breast, colorectal, endometrial, lung, ovarian, pancreatic, gastrointestinal tract or prostate cancer. Preference is given to young investigators with documented evidence of potential for conducting novel research of either basic or clinical aspects of cancer and cancer-related problems. Applications from established investigators exploring new and innovative areas of cancer research also will be considered. Post-doctoral fellows are not eligible. View full application information. Direct questions to Marcy Colley, marcycolleypbp@gmail.com. Applications for grants must be submitted to the office of the National Second Vice President by Thursday, June 15.
|
|
Request for Applications: Pediatric Sarcomas
The Samuel Waxman Cancer Research Foundation, Alan B. Slifka Foundation and Israel Cancer Research Fund are pleased to issue a joint request for applications for collaborative applications focused on fusion-positive pediatric sarcomas. Note: Projects must involve collaboration between two research groups — one in North America and one in Israel — with different but complementary expertise. Proposals must justify the partnership through synergistic scientific aims. One successful collaborative project will be awarded $150,000 per year for two years, or a total of $300,000, with each university-based research group receiving $75,000 per year ($150,000). Proposals will be prioritized for funding based on their potential to contribute to understanding, preventing and effectively treating pediatric sarcomas, with an emphasis on Ewing sarcoma. View full RFA information. Submit letter of intent by 5 p.m. on May 1, to Wylie Tene at wtene@waxmancancer.org.
|
|
Federal Lung Cancer Funding Opportunities
The Lung Cancer Research Program (LCRP), part of the Congressionally Directed Medical Research Programs, has released its fiscal year 2023 funding opportunities. The LCRP looks to support highly innovative, high-risk early ideas as well as more advanced translation research and early stage clinical trials. In addition, it supports researcher development with a career development-focused award mechanism. Pre-application (letter of intent) is required. Direct questions to help@eBRAP.org or 301-682-5507. View the funding opportunities and application instructions for:
-
Career Development Award, Pre-application due May 2, 5:00 p.m. ET
-
Concept Award, Pre-application due May 2, 5:00 p.m. ET
-
Idea Development Award: Pre-application due May 10, 5:00 p.m. ET
-
Translational Research Award: Pre-application due May 10, 5:00 p.m. ET
|
|
Children’s Cancer Foundation 2023 Call for Proposals
The Children's Cancer Foundation, Inc. (CCF) invites individuals from Maryland, D.C. and Northern Virginia conducting research and/or programs relevant to pediatric cancer to submit proposals for grant award consideration. CCF will be awarding multiple one-year grants for research; one one-year grant for research by a young investigator (Giant Food NextGen Award); and several one-year grants for support of an existing or new program that serves the pediatric cancer community. Applications must be submitted via email or file transfer service to Rose Ann Verrilli: rverrilli@childrenscancerfoundation.org no later than May 7 at 11:59 p.m. ET. Review and download application materials and guidelines.
|
|
Research With Activities Related to Diversity (ReWARD)
The ReWARD program provides support for the health-related research of scientists who are making a significant contribution to Diversity, Equity, Inclusion, and Accessibility (DEIA) and who have no current NIH research project grant funding. The ReWARD program provides funding for both the scientific research and the DEIA activities of investigators. The grant will support scientific research in areas related to the programmatic interests of one or more of the participating NIH Institutes and Centers and ongoing DEIA activities focused on enhancing diversity in the biomedical research enterprise within the United States and territories. View more information and application instructions. Application due date: Monday, June 5, at 5:00 p.m.
|
|
Meetings in italics should be attended by all fellows.
|
|
9:00 AM | Breast Research Meeting | Podium A / Zoom (dial 646-558-8656; Meeting ID: 528212194)
11:00 AM | GU/Melanoma Research Meeting | Podium A / Zoom (dial 646-558-8656; Meeting ID: 796253566)
12:15 PM | Journal Club – Christian Agbisit, Dr. Noel | Podium A / Zoom
4:00 PM | GU Tumor Board (on 1st/3rd Mondays of the month) | Podium A / Zoom (dial 646-558-8656; Meeting ID: 869742463)
|
|
9:00 AM | Hematology Path Conference - Inpatient Heme fellows + Outpatient Heme + BMT fellow | Podium A / Microsoft Teams (CME code: 80737; phone: 202-796-7323)
12:15 PM | Guest Lecturer – Dr. Alan Venook (UCSF) | Podium A / Zoom
4:00 PM | Liver Tumor Board | WebEx (dial 844-302-0362; Meeting number (access code): 711 507 430, password: Mse4mGSA2N5)
5:00 PM | Breast Tumor Board | Podium A / Zoom (dial 646-558-8656; Meeting ID: 93777073374; CME code: 80044)
|
|
8:00 AM | Thoracic Tumor Board – Thoracic Fellow | Podium A / Zoom (dial 646-558-8656; Meeting ID: 941 1630 5835)
12:15 PM | No Conference |
|
|
9:00 AM | Cancer Research Data Meeting | None | W302 New Research Building or Zoom
9:30 AM | Head and Neck Tumor Board - Thoracic Fellow attendance encouraged as clinic allows | Microsoft Teams
12:15 PM | Heme ITE Review | Podium A / Zoom
12:30 PM | GI Research Meeting | WebEx (dial 844-302-0362, Meeting Number (access code): 712527865, HOST PIN: 5514)
|
|
7:00 AM | CNS Tumor Board | Zoom (dial 646-558-8656; Meeting ID: 378 807 316)
12:00 PM | Oncology Grand Rounds Lecture Series: None | Zoom
12:00 PM | No Lecture |
|
|
Connect with Georgetown Lombardi on Social Media |
|
If you would like to share news or updates from your department, please get in touch with Sarah Riehl. |
|
|
|
|
|
|
